||Amgen Increases Price of Anemia Drug for Dialysis Patients
Article from Nephrology News & Issues.
Editor's note: Amgen has enjoyed a monopoly within Medicare and 90% margins in a largely taxpayer-funded, multi-billion-dollar marketplace for 24 years. Amgen has made more profit, by far, than any other company from the care of dialysis patients.
This is unprecedented profit in the history of U.S. business. A 90% margin means that if the dialysis clinic pays $100 for the product, Amgen makes $90 profit. $10 covers the cost of manufacturing, marketing, administration, FDA compliance, etc. With one short-time exception, Amgen has had enjoyed a monopoly on ESAs in the U.S. dialysis market since 1989.
Now Amgen wants even more of the taxpayer-funded pool of money for dialysis. This is unprecedented greed in the history of medicine.
Are there any dialysis patient advocacy groups who see this situation as not serving the best interests of patients... or taxpayers?